

**Best & Largest Award from Exame Magazine pointed Blau Farmacêutica as the Company with highest return on equity in the pharmaceutical industry**  
*The Company was also the fastest growing in the industry*

Yesterday, 45th edition of the Best and Largest Award from Exame Magazine took place, which elected the companies that stood out the most in 20 sectors of the Brazilian economy in 2017. BLAU Farmacêutica stood out among the best pharma companies by winning the 6th place in the general ranking, and the 1st place in two categories: "Growth" - net sales increase in the year - already discounting inflation, with 37,2%; and "Profitability" - return on equity - with 50,7%.

As for "Wealth per Employee" category - wealth generated per employee in USD - the Company appeared in the 10th place with US\$87.941, which reinforces the corporate strategy of investing in human capital in operational effectiveness.

Also, according to the publication, the Company achieved the highest return on equity in the industry (51%). BLAU Farmacêutica was also the fastest growing in the industry (37%) and earned US\$185 million.

#### **Performance**

Presenting a Net Revenue of R\$334 million and EBITDA of R\$79 million in the first half of 2018, BLAU Farmacêutica achieved its best performance in the private segment both in the first half and second quarter of 2018, up 24,1% and 52,1% against the previous year. This result further strengthens its leadership position as one of the largest non-retail companies (hospital and clinics) in Latin America.

#### **About BLAU**

Founded in 1987, BLAU Farmacêutica is one of the leading pharmaceutical companies in Latin America in the non-retail segment, with 100% Brazilian capital, which develops and produces high complexity drugs essential for human health - biologics, specialties, oncology, among others - and marketed with proprietary brands.

Established in the metropolitan center of São Paulo, Blau Farmacêutica has a modern pharmaceutical industrial complex, composed of four manufacturing plants, with state-of-the-art technology, dedicated to medicines production as biological, biotechnological, oncological, antibiotic, injectable, and biotechnological API (active pharmaceutical ingredients).

Investor Relations

E-mail • [ir@blau.com](mailto:ir@blau.com)

Phone • +55 (11) 4615-9413

Website • [ir.blau.com](http://ir.blau.com)